Amalgent Therapeutics is developing combination drugs that dramatically reduce the doses required for effective analgesia.
Amalgent Therapeutics has raised $250K in total funding. The most recent round was Debt Financing. The last funding was announced in February 2023.
Amalgent Therapeutics's investors include North Carolina Biotechnology Center.
Amalgent Therapeutics is headquartered in Greenville, United States.
Amalgent Therapeutics is developing combination drugs that dramatically reduce the doses required for effective analgesia.
Amalgent Therapeutics is at the Debt Financing stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Amalgent Therapeutics — Funding & Investors." VCBacked, February 16, 2023, https://www.vcbacked.co/company/amalgent-therapeutics. Accessed August 14, 2026.
VCBacked. (2023). Amalgent Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/amalgent-therapeutics
{{cite web |title=Amalgent Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/amalgent-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated